Cannabis has been found to increase the risk of deadly liver damage. The US FDA’s Center for Drug Evaluation and Research conducted a randomized double-blind clinical trial – the gold standard for scientific research – and found dangerous liver enzyme spikes in people who consumed cannabis.
AI Overview
The FDA has identified the potential for liver injury, particularly elevated liver enzymes, with the use of cannabis-derived compounds, especially cannabidiol (CBD). While the FDA-approved CBD drug Epidiolex has shown some cases of liver problems in patients, particularly at higher doses and when combined with certain medications like valproate and clobazam, the risk is generally considered lower with lower doses of over-the-counter CBD products.
Key points about cannabis, CBD, and liver enzymes:
- FDA Concerns:The FDA has acknowledged potential liver injury associated with CBD use, especially at higher doses.
- Dose-Dependent Risk:Higher doses of CBD have been linked to a greater likelihood of liver enzyme elevations and drug-induced liver injury (DILI), while the risk at lower doses commonly found in dietary supplements is considered lower.
- Drug Interactions:CBD can interact with other medications by affecting the liver’s ability to metabolize them, potentially increasing the risk of side effects or reducing their effectiveness, particularly with certain antiepileptic drugs.
- Research Findings:Studies suggest that while CBD is generally well-tolerated, especially at lower doses, careful monitoring is recommended for individuals taking higher doses or with pre-existing liver conditions.
- Clinical Guidance:Clinicians are advised to screen for CBD use in patients presenting with elevated liver enzymes and to consider CBD-associated hepatotoxicity in the differential diagnosis.
